AbbVie Inc. reported second-quarter 2026 revenue of USD 16.99 billion, representing a 10.20 percent year-over-year increase. The company also delivered adjusted earnings per share of USD 3.65, which beat the market consensus estimate of USD 3.61 by four cents. This positive performance provides a solid baseline as investors await the upcoming third-quarter results. Market analysts and data providers project AbbVie's third-quarter revenue to reach USD 17.34 billion with adjusted earnings per share expected at USD 3.80. The company is scheduled to release these Q3 figures on October 30, 2026, before the market opens, followed by a conference call at 9:00 a.m. ET. These upcoming metrics will serve as critical tests against the higher revenue bar set for the quarter. Equity research firm Morgan Stanley recently raised its price target for AbbVie from USD 296.00 to USD 310.00 while maintaining an overweight rating, signaling continued confidence in the stock's trajectory. Additionally, AbbVie has an ex-dividend date of October 15, 2026, offering a quarterly dividend of USD 1.73 per share, providing near-term value to shareholders alongside the anticipated earnings release. Currently trading at EUR 245.55, AbbVie stock sits approximately 3.06 percent below its 52-week high of EUR 253.30. With a market capitalization of EUR 434.6 billion, the pharmaceutical giant operates within the Healthcare sector and is positioned to deliver results that could influence its valuation relative to recent highs.